Medline: 2729175

American Journal of Clinical Oncology 12(3): 190-194, 1989.

Comprehensive lymphatic irradiation for stage II-III non-Hodgkin's lymphoma.

Mendenhall NP, Million RR


Thirteen patients with Stage II-III non-Hodgkin's lymphoma (NHL) and one patient with minimal marrow involvement were selected for treatment between 1964 and 1986 with moderate-dose comprehensive lymphatic irradiation (CLI). This approach has been well tolerated and has produced relapse-free and overall survival rates at 10 years of 60 and 66%, respectively. Salvage therapy for failure following CLI has been possible. CLI produces results comparable to any achieved with combined modality therapy, offers less acute and late toxicity, and requires only 3-4 months for completion.

This is a service of:

Uni Logo

Rheinische Friedrich- Wilhelms- Universität Bonn
Medical Center

Dr. G. Quade